Learn More-External Link
Trending at Lumira Ventures
Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by Soluble CD83…
Learn More-External Link
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Learn More-External Link
Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech
Learn More-External Link
Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates…
Learn More-External Link
Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it will receive a $1 million milestone payment from its collaborator Nuvelo, Inc. The milestone payment has been triggered by Nuvelo’s enrollment …
Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy..
DURHAM, N.C.–(BUSINESS WIRE)–Argos Therapeutics today announced the publication of an article in the peer-reviewed online journal PLoS ONE supporting the company’s novel approach to stimulating a patient-specific immune response to HIV infection. The present study describes the adaptation of Argos’ …
Avalon Pharmaceuticals Announces the Initiation of Compound Characterization Phase in Drug Discovery
GERMANTOWN, Md., Jan 14, 2008 (BUSINESS WIRE) — Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), today announced the initiation of the next phase in its drug discovery collaboration with Novartis. The collaboration aims to discover small molecule therapeutic compounds targeted against a …
Vermillion Provides 2008 Outlook for Its High-Value Diagnostic Products
Learn More-External Link
TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Mali
Learn More-External Link
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study…
Learn More-External Link
Cardiac Dimensions® Inc. Announces Closing of $35.5 Million Round of Financing. JJDC & Lumira Capital Co-Lead Round, Providing Funds to Be Used to Support FDA Clinical Trials of the CARILLON™ Mitral Contour System™
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, Inc. announced today it has closed $35.5 million in new venture capital. This Series D financing was co-led by Johnson & Johnson Development Corp. (JJDC) and Lumira Capital, and included Mitsubishi UFJ Capital, West River Capital, …
Immunicon Corporation Announces Independent Studies to Be Presented at 2007 San Antonio Breast Cancer Symposium That Confirm Utility of the CellSearch™ Circulating Tumor Cell Kit
HUNTINGDON VALLEY, Pa. & SAN ANTONIO–(BUSINESS WIRE)–Immunicon Corporation (NASDAQ-CM:IMMC) announced today that three independent studies featuring Immunicon’s CellTracks® technology and the CellSearch™ Circulating Tumor Cell Kit will be presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS). The …
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ — Pharmasset, Inc. announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis …
Replidyne Provides Strategic Update
LOUISVILLE, Colo., Dec. 10 /PRNewswire-FirstCall/ — Replidyne, Inc. today announced an operational restructuring to align critical resources with strategic priorities. These priorities include identifying a partner for Replidyne’s late-stage antibiotic, faropenem medoxomil (faropenem), advancing and expanding its infectious disease pipeline, …